Expression of LMO4 and outcome in pancreatic ductal adenocarcinoma

Br J Cancer. 2008 Feb 12;98(3):537-41. doi: 10.1038/sj.bjc.6604177. Epub 2008 Jan 29.

Abstract

Identification of a biomarker of prognosis and response to therapy that can be assessed preoperatively would significantly improve overall outcomes for patients with pancreatic cancer. In this study, patients whose tumours exhibited high LMO4 expression had a significant survival advantage following operative resection, whereas the survival of those patients whose tumours had low or no LMO4 expression was not significantly different when resection was compared with operative biopsy alone.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adaptor Proteins, Signal Transducing
  • Adenocarcinoma / metabolism*
  • Adenocarcinoma / surgery
  • Adult
  • Aged
  • Aged, 80 and over
  • Biomarkers, Tumor / analysis
  • Carcinoma, Pancreatic Ductal / metabolism*
  • Carcinoma, Pancreatic Ductal / surgery
  • Cohort Studies
  • Female
  • Homeodomain Proteins / metabolism*
  • Humans
  • LIM Domain Proteins
  • Male
  • Middle Aged
  • Pancreatectomy
  • Pancreatic Neoplasms / metabolism*
  • Pancreatic Neoplasms / surgery
  • Prognosis
  • Survival Analysis
  • Transcription Factors / metabolism*
  • Treatment Outcome

Substances

  • Adaptor Proteins, Signal Transducing
  • Biomarkers, Tumor
  • Homeodomain Proteins
  • LIM Domain Proteins
  • LMO4 protein, human
  • Transcription Factors